A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma

Summary

This is a national multicenter, randomized controlled, open, dose-optimized Phase IV study. It is expected to enroll approximately 88 patients with relapsed/refractory indolent B-cell lymphoma. The aim is to evaluate the efficacy and safety of linperlisib in the treatment of patients with relapsed/refractory indolent B-cell lymphoma at two doses/modes of administration (clinically recommended dose/mode and optimized dose/mode).

Timeline

Start

2024-04-30

Primary completion

2024-04-30

Completion

2025-04-30

Drugs

Indications